IMS Institute for Healthcare Informatics Issues Forecast for Global Medicine Use - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

IMS Institute for Healthcare Informatics Issues Forecast for Global Medicine Use

ePT--the Electronic Newsletter of Pharmaceutical Technology

A report from the IMS Institute for Healthcare Informatics, The Global Use of Medicines: Outlook through 2016, found that annual global spending on medicines will rise from $956 billion in 2011 to nearly $1.2 trillion in 2016, the Institute said in a July 12, 2012, press release. According to the study, growth is expected to rebound from a low of 3–4% in 2012 to 5–7% in 2016, driven by volume increases in pharmerging markets and spending increases in developed nations.

In developed nations, the high level of patent expiries will limit branded medicine growth, but this will be offset by increased generics spending. In the US, medicine use is predicted to grow at an average annual rate of 1–4% over the next 5 years, driven by expanded patient access expected from the implementation of the Affordable Care Act in 2014 and by new medicines for currently unmet needs. Globally, 160–185 new molecular entities are expected to launch between 2011 and 2016, compared to 142 launches between 2007 and 2011, according to the report.

Medicine spending in emerging pharmaceutical markets is expected to double in the next five years due to rising incomes, low drug costs, and government-sponsored programs to increase access. Over 80% of this increase, however, will come from generics, OTC medicines, diagnostics, and nontherapeutics, estimated the IMS Institute.

“The trillion-dollar spending on medicines we forecast for 2016 represents a rebound in growth that will accentuate the challenges of access and affordability facing those who consume and pay for healthcare around the world,” said Murray Aitken, executive director of the IMS Institute, in the release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here